Glycine Treatment of Prodromal Symptoms

Yale University10 enrolled

Overview

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Schizophrenia

Interventions

glycineDRUG

0.8 g/kg/day

Eligibility

Sex: ALLMin age: 14 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age 14-35 * meets SIPS criteria for psychosis prodrome Exclusion Criteria: * current antipsychotic medication * more than 4 weeks of antipsychotic medication lifetime

Outcomes

Primary Outcomes

Scale Of Prodromal Symptoms total score

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.